3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
91
Stomach Neoplasms
44
Pancreatic Neoplasms
37
Rectal Neoplasms
29
Colonic Neoplasms
23
Neoplasms
22
Esophageal Neoplasms
21
Squamous Cell Carcinoma of Head and Neck
20
Neoplasm Metastasis
18
Cholangiocarcinoma
16
Adenocarcinoma Of Esophagus
16
Biliary Tract Neoplasms
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Head and Neck Neoplasms
12
Esophageal Squamous Cell Carcinoma
12
Carcinoma, Non-Small-Cell Lung
12
Adenocarcinoma
12
Urinary Bladder Neoplasms
11
Ovarian Neoplasms
9
Gastrointestinal Neoplasms
9
Carcinoma, Hepatocellular
7
Endometrial Neoplasms
6
Breast Neoplasms
6
Gallbladder Neoplasms
5
Advanced Solid Tumors
5
Uterine Cervical Neoplasms
4
Peritoneal Neoplasms
4
Lung Neoplasms
4
Carcinoma
4
Appendiceal Neoplasms
4
Interventions
Nivolumab
3
capivasertib
2
Gemcitabine
2
Cisplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Lenalidomide
1
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Fluorouracil
×
1 year
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts